- Home
- Media Center
- Press releases
- Corporate
Corporate
Janssen Initiates FIRST, a Novel Study to Evaluate the Benefit of Caregiver Education in Improvement of Outcomes for Patients with Serious Mental Illness
New Study Examines Link between Caregiver Education and Patient Outcomes
Your Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV Community Organizations
Notable HIV Advocates Highlight Perspectives of People Living with or Affected by HIV to Leverage Shared Support and Self-Expression
New Global Real-World Data from Atrial Fibrillation Studies Confirm the Safety Profile of XARELTO®
Global evidence from EXPLORER research program reports real-world bleeding rates in XARELTO® (rivaroxaban) patients with non-valvular atrial fibrillation
CELLSEARCH® System Recognized as Landmark Innovation in Cancer Research
Seminal Study included in list of Most Significant Publications of past 20 years in Clinical Cancer Research.
Phase 2B Findings Published In The New England Journal Of Medicine Demonstrate Significant Efficacy Of Guselkumab In Treatment Of Moderate To Severe Plaque Psoriasis
Guselkumab, an anti-interleukin-23 monoclonal antibody, showed improvements in primary and secondary endpoints compared with placebo and active comparator adalimumab, an anti-tumor necrosis factor-alpha agent
Daratumumab Expanded Access Program Open to Eligible U.S. Patients with Heavily Pre-Treated Multiple Myeloma
Janssen, with support from the Multiple Myeloma Research Foundation, opens EAP to help patients in immediate need of new treatment options
Investigational HIV Vaccine Regimen Shows Encouraging Results in Non-Human Primates
Pre-Clinical Data Published in Science Forms Basis for Early Human Clinical Trials